# Calibra Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/calibra-medical

- Industry: Medical Devices & Equipment
- Headquarters: Redwood City, US
- Website: www.myfinesse.com
- Total disclosed funding: $61M
- Latest round: Series D (Apr 1, 2011)
- Investors on record: 5

## About

Calibra Medical is a healthcare company focused on developing innovative solutions that enhance the management of diabetes, particularly through advanced medical devices.Calibra Medical specializes in creating medical devices designed to improve diabetes care. The company was acquired by Johnson & Johnson's LifeScan business unit in July 2012, with undisclosed financial terms. Located in Redwood City, US, it operates within a highly competitive market. The founder's history is not publicly available.MyFinesse.com specializes in the sale and leasing of domain names, providing a streamlined platform where customers can acquire internet domains in a secure and efficient manner. The primary offerings include a straightforward purchase option priced at USD 4,995, as well as a Lease to Own plan at USD 714 per month. These services cater to a diverse clientele ranging from individual entrepreneurs to established businesses seeking an online presence, allowing them to either outright purchase or gradually obtain ownership of domain names. The company's operational model emphasizes user-friendly transactions, with features such as free transaction support and secure payment options. MyFinesse.com serves a global market, providing local currency options during checkout, ensuring accessibility for a wide array of customers across different geographical regions.The revenue model at MyFinesse.com is primarily driven by direct transactions related to domain name sales and leasing agreements. When a customer opts to purchase a domain, the transaction is executed at the listed price of USD 4,995, while the Lease to Own option generates recurring monthly revenue through the USD 714 payment structure. This model attracts a variety of customers, including startups and small businesses, who may prefer the flexibility of leasing over a large upfront payment. The company leverages a direct-to-consumer approach, facilitating seamless transactions that prioritize customer support and security. By focusing on these specific offerings, MyFinesse.com establishes a consistent revenue stream through its core services, ensuring a sustainable business model within the domain marketplace.In July 2012, following the acquisition by Johnson & Johnson's LifeScan business unit, Calibra Medical will focus on enhancing its product offerings in diabetes management. The company aims to integrate advanced technological features into its devices, targeting a release by the end of the fiscal year. This will support its strategy to expand into new markets across North America and Europe. The funding received from the Series D round, which raised USD 8.100 mn, will be directed towards research and development to facilitate these new product launches and market expansions.

## Funding rounds

- Series D, Apr 1, 2011, $8.1M — Frazier Healthcare Partners, Intersouth Partners, Canaan Partners, Three Arch Partners
- Series C, Feb 9, 2010, $9.3M — Frazier Healthcare Partners, Intersouth Partners, Canaan Partners, Three Arch Partners
- Series B, Aug 1, 2008, $35M — Frazier Healthcare Partners, Intersouth Partners, Canaan Partners, Three Arch Partners, Skyline Ventures
- Series A, Oct 1, 2006, $8.6M — Frazier Healthcare Partners, Three Arch Partners

## Investors

- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A, Series B, Series C, Series D
- Three Arch Partners (https://capitalatlas.ai/funds/three-arch-partners) — Series A, Series B, Series C, Series D
- Intersouth Partners (https://capitalatlas.ai/funds/intersouth-partners) — Series B, Series C, Series D
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series B, Series C, Series D
- Skyline Ventures (https://capitalatlas.ai/funds/skyline-ventures) — Series B